Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.30 |
| ▸ | YTHDF2 | Q9Y5A9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2139275 | 0.76 | PDPK1 (0.35) | PDPK1 | |
| SCHEMBL442759 | 0.72 | PNP (0.32) | XDHPDPK1 | |
| SCHEMBL3444335 | 0.72 | CSNK2A1 (0.34) | — | |
| SCHEMBL8169178 | 0.72 | BCL2 (0.34) | — | |
| SCHEMBL9426162 | 0.72 | — | — | |
| SCHEMBL21913 | 0.72 | YTHDC1 (0.47) | XDHPDPK1YTHDC1YTHDF2 | |
| SCHEMBL545951 | 0.72 | PDPK1 (0.37) | PDPK1 | |
| SCHEMBL546075 | 0.72 | XDH (0.53) | XDH | |
| SCHEMBL18941356 | 0.71 | SYK (0.37) | — | |
| SCHEMBL6272986 | 0.71 | YTHDC1 (0.46) | XDHPDPK1YTHDC1YTHDF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-11015194-B2 | iRNA agents with biocleavable tethers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | BANK OF AMERICA, N.A. | 2020-08-13 | — | — | US | disclosed |
| US-10676740-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-06-09 | — | — | US | disclosed |
| WO-2004094595-A2 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004091515-A2 | iRNA CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
| US-6110923-A | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity | BIOCHEM PHARMA INC. (CA) | 2000-08-29 | — | — | US | disclosed |
| US-5994361-A | ANTITUMOR, ANTICANCER AGENT | BIOCHEM PHARMA (CA) | 1999-11-30 | — | — | US | disclosed |
| EP-0766683-A1 | NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | BIOCHEM PHARMA INC (CA) | 1997-04-09 | — | — | EP | disclosed |
| WO-1995035297-A1 | NOVEL SUBSTITUTED PURINYL DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | BIOCHEM PHARMA INC. (CA) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220403377-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | XDH 2450/4885PDPK1 2827/4885YTHDC1 3421/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | XDH 4617/4885PDPK1 3389/4885YTHDC1 1682/4885 |
| US-20200255833-A1 | THERAPEUTIC COMPOSITIONS | SNRPE, HNRNPH3, RNASE1 | XDH 4309/4885PDPK1 3170/4885YTHDC1 1211/4885 |
| US-10676740-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | XDH 2450/4885PDPK1 2827/4885YTHDC1 3421/4885 |
| US-11530408-B2 | Therapeutic compositions | SNRPE, HNRNPH3, RNASE1 | XDH 4309/4885PDPK1 3170/4885YTHDC1 1211/4885 |
| US-11312957-B2 | Modified iRNA agents | NCL, HNRNPA0, HNRNPA1 | XDH 2450/4885PDPK1 2827/4885YTHDC1 3421/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | XDH 2529/4885PDPK1 4540/4885YTHDC1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.